332 related articles for article (PubMed ID: 36356699)
21. Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study.
Barton JR; Woelkers DA; Newman RB; Combs CA; How HY; Boggess KA; Martin JN; Kupfer K; Sibai BM;
Am J Obstet Gynecol; 2020 Mar; 222(3):259.e1-259.e11. PubMed ID: 31518550
[TBL] [Abstract][Full Text] [Related]
22. Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology.
Romero R; Jung E; Chaiworapongsa T; Erez O; Gudicha DW; Kim YM; Kim JS; Kim B; Kusanovic JP; Gotsch F; Taran AB; Yoon BH; Hassan SS; Hsu CD; Chaemsaithong P; Gomez-Lopez N; Yeo L; Kim CJ; Tarca AL
Am J Obstet Gynecol; 2022 Oct; 227(4):615.e1-615.e25. PubMed ID: 36180175
[TBL] [Abstract][Full Text] [Related]
23. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F
Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800
[TBL] [Abstract][Full Text] [Related]
24. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction.
Arenas GA; Tang NY; Mueller A; Lopes Perdigao J; Kaur H; Abramowicz JS; Mussatt K; Yeo KJ; Rana S
Am J Obstet Gynecol MFM; 2021 Jul; 3(4):100394. PubMed ID: 33991706
[TBL] [Abstract][Full Text] [Related]
25. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension?
Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
Ultrasound Obstet Gynecol; 2022 Feb; 59(2):192-201. PubMed ID: 34165863
[TBL] [Abstract][Full Text] [Related]
26. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
[TBL] [Abstract][Full Text] [Related]
27. Prenatal screening for preeclampsia: the roles of placental growth factor and pregnancy-associated plasma protein A in the first trimester and placental growth factor and soluble fms-like tyrosine kinase 1-placental growth factor ratio in the early second trimester.
Huang T; Rashid S; Priston M; Rasasakaram E; Mak-Tam E; Gibbons C; Mei-Dan E; Bedford HM
AJOG Glob Rep; 2023 May; 3(2):100193. PubMed ID: 37168546
[TBL] [Abstract][Full Text] [Related]
28. The implications of the Fetal Medicine Foundation 35- to 36-week preeclampsia prediction competing-risk model on timing of birth.
von Dadelszen P; Syngelaki A; Wright A; Akolekar R; Magee LA; Wright D; Nicolaides KH
Am J Obstet Gynecol; 2023 Apr; 228(4):457.e1-457.e7. PubMed ID: 36206987
[TBL] [Abstract][Full Text] [Related]
29. Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy.
Palomo M; Youssef L; Ramos A; Torramade-Moix S; Moreno-Castaño AB; Martinez-Sanchez J; Bonastre L; Pino M; Gomez-Ramirez P; Martin L; Garcia Mateos E; Sanchez P; Fernandez S; Crovetto F; Escolar G; Carreras E; Castro P; Gratacos E; Crispi F; Diaz-Ricart M
Am J Obstet Gynecol; 2022 Aug; 227(2):277.e1-277.e16. PubMed ID: 35351411
[TBL] [Abstract][Full Text] [Related]
30. Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction.
Dathan-Stumpf A; Czarnowsky V; Hein V; Andraczek T; Stepan H
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1037-S1047.e2. PubMed ID: 33892922
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia.
Verlohren S; Dröge LA
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1048-S1058. PubMed ID: 33002498
[TBL] [Abstract][Full Text] [Related]
32. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.
Buhimschi CS; Baumbusch MA; Dulay AT; Lee S; Wehrum M; Zhao G; Bahtiyar MO; Pettker CM; Ali UA; Funai EF; Buhimschi IA
BJOG; 2010 Feb; 117(3):321-30. PubMed ID: 19943826
[TBL] [Abstract][Full Text] [Related]
33. The impact of the definition of preeclampsia on disease diagnosis and outcomes: a retrospective cohort study.
Reddy M; Fenn S; Rolnik DL; Mol BW; da Silva Costa F; Wallace EM; Palmer KR
Am J Obstet Gynecol; 2021 Feb; 224(2):217.e1-217.e11. PubMed ID: 32795430
[TBL] [Abstract][Full Text] [Related]
34. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome.
Stepan H; Hund M; Andraczek T
Hypertension; 2020 Apr; 75(4):918-926. PubMed ID: 32063058
[TBL] [Abstract][Full Text] [Related]
35. Serum amyloid A1 and pregnancy zone protein in pregnancy complications and correlation with markers of placental dysfunction.
Fosheim IK; Jacobsen DP; Sugulle M; Alnaes-Katjavivi P; Fjeldstad HES; Ueland T; Lekva T; Staff AC
Am J Obstet Gynecol MFM; 2023 Jan; 5(1):100794. PubMed ID: 36334725
[TBL] [Abstract][Full Text] [Related]
36. Chronic hypertension and superimposed preeclampsia: screening and diagnosis.
Kametas NA; Nzelu D; Nicolaides KH
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1182-S1195. PubMed ID: 35177217
[TBL] [Abstract][Full Text] [Related]
37. The role of angiogenic factors in the management of preeclampsia.
Flint EJ; Cerdeira AS; Redman CW; Vatish M
Acta Obstet Gynecol Scand; 2019 Jun; 98(6):700-707. PubMed ID: 30667052
[TBL] [Abstract][Full Text] [Related]
38. Circulating angiogenic factors are associated with progression to preeclampsia and the occurrence of adverse outcomes in women with gestational hypertension.
Nolasco-Leaños AG; Ramírez-Valenzuela KL; Carrillo-Juárez RI; Molina-Pérez CJ; Isordia-Salas I; Leaños-Miranda A
J Hypertens; 2021 Mar; 39(3):573-580. PubMed ID: 33149103
[TBL] [Abstract][Full Text] [Related]
39. A prognostic model to guide decision-making on timing of delivery in late preterm pre-eclampsia: the PEACOCK prospective cohort study.
Duhig K; Seed PT; Placzek A; Sparkes J; Gill C; Brockbank A; Shennan A; Thangaratinam S; Chappell LC
Health Technol Assess; 2021 May; 25(30):1-32. PubMed ID: 34024312
[TBL] [Abstract][Full Text] [Related]
40. Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio.
Villalaín C; Herraiz I; Valle L; Mendoza M; Delgado JL; Vázquez-Fernández M; Martínez-Uriarte J; Melchor Í; Caamiña S; Fernández-Oliva A; Villar OP; Galindo A
J Am Heart Assoc; 2020 Apr; 9(7):e015548. PubMed ID: 32248765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
